Antitumor necrosis factor treatment for pediatric inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 18, Issue 5, 2012, Pages 985-1002

  De Bie, Charlotte I ^a   Escher, Johanna C ^a   De Ridder, Lissy ^a  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Adalimumab; Certolizumab; Infliximab; Pediatric inflammatory bowel disease

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; MERCAPTOPURINE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ABSCESS; ACUTE INFUSION REACTION; ANTIBODY PRODUCTION; APPENDICITIS; BASAL CELL CARCINOMA; CANCER RISK; CARDIOMYOPATHY; CELLULITIS; CHICKENPOX; CLOSTRIDIUM DIFFICILE INFECTION; COLON CARCINOMA; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DEPRESSION; DERMATOMYCOSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENTERITIS; GASTROENTERITIS; GROWTH RETARDATION; HEART ARREST; HEART FAILURE; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HEPATOSPLENIC T CELL LYMPHOMA; HERPES ZOSTER; HISTOPLASMOSIS; HODGKIN DISEASE; HUMAN; LISTERIOSIS; LONG QT SYNDROME; LOW DRUG DOSE; MYCOSIS; MYOCARDITIS; OPPORTUNISTIC INFECTION; OSTEOMYELITIS; PANCREATITIS; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSEUDOMEMBRANOUS COLITIS; PSEUDOMONAS INFECTION; PSORIASIS; RASH; REVIEW; SEPSIS; SIDE EFFECT; T CELL LYMPHOMA; TINEA; TREATMENT OUTCOME; VASCULITIS; VIRUS REACTIVATION; CHILD; DRUG ANTAGONISM; IMMUNOLOGY; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; CHILD; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859788279     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21871     Document Type: Review

References (171)

1. Auvin S, Molinie F, Gower-Rousseau C, et al. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988-1999). J Pediatr Gastroenterol Nutr. 2005;41:49-55. (Pubitemid 40967355)
2. Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17:423-439.
3. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135:1114-1122.
4. Sauer CG, Kugathasan S. Pediatric inflammatory bowel disease: highlighting pediatric differences in IBD. Med Clin North Am. 2010;94:35-52.
5. Van Assche G, Dignass A, Reinisch W, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohns Colitis. 2010;4:63-101.
6. Biancone L, Michetti P, Travis S, et al. European evidence-based Consensus on the management of ulcerative colitis: special situations. J Crohns Colitis. 2008;2:63-92. (Pubitemid 351179489)
7. Remicade approved for children with Crohn's disease. FDA Consum. 2006;40:6.
8. Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149-160. (Pubitemid 351160153)
9. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology. 1994;106:1455-1466. (Pubitemid 24163114)
10. Tsukada Y, Nakamura T, Iimura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol. 2002;97:2820-2828. (Pubitemid 35265434)
11. Horiuchi T, Mitoma H, Harashima S, et al. Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology (Oxford). 2010;49:1215-1228.
12. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 1993;30:1443-1453.
13. Kozuch PL, Hanauer SB. General principles and pharmacology of biologics in inflammatory bowel disease. Gastroenterol Clin North Am. 2006;35:757-773. (Pubitemid 44791839)
14. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13:1323-1332. (Pubitemid 350206841)
15. Kaymakcalan Z, Sakorafas P, Bose S, et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol. 2009;131:308-316.
16. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094. (Pubitemid 33022088)
17. Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:888-893. (Pubitemid 43994545)
18. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002;50:206-211. (Pubitemid 34087933)
19. Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785. (Pubitemid 36666774)
20. Shen C, Assche GV, Colpaert S, et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther. 2005;21:251-258. (Pubitemid 40278362)
21. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum. 2008;58:1248-1257. (Pubitemid 351705913)
22. Vos AC, Wildenberg ME, Duijvestein M, et al. Anti-tumor necrosis factor-alpha antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology. 2011;140:221-230.
23. Derkx B, Taminiau J, Radema S, et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet. 1993;342:173-174. (Pubitemid 23200450)
24. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
25. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. (Pubitemid 34621118)
26. Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr. 2000;137:192-196. (Pubitemid 30659226)
27. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol. 2000;95:3189-3194.
28. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol. 2003;98:833-838. (Pubitemid 36576310)
29. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2003;36:632-636. (Pubitemid 39274589)
30. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther. 2003;18:425-431. (Pubitemid 37070241)
31. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig Liver Dis. 2004;36:342-347. (Pubitemid 41115465)
32. Lamireau T, Cezard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis. 2004;10:745-750. (Pubitemid 39545219)
33. Afzal NA, Ozzard A, Keady S, et al. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig Dis Sci. 2007;52:3329-3333. (Pubitemid 350077184)
34. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007;132:863-873; quiz 1165-1166.
35. Wynands J, Belbouab R, Candon S, et al. 12-month follow-up after successful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46:293-298.
36. Ruemmele FM, Lachaux A, Cezard JP, et al. Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis. 2009;15:388-394.
37. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J Pediatr Gastroenterol Nutr. 2004;39:46-52.
38. Crandall W, Hyams J, Kugathasan S, et al. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J Pediatr Gastroenterol Nutr. 2009;49:183-190.
39. Teitelbaum JE, Saeed S, Triantafyllopoulou M, et al. Infliximab in pediatric Crohn disease patients with enterovesicular fistulas. J Pediatr Gastroenterol Nutr. 2007;44:279-282. (Pubitemid 46175086)
40. Afzal NA, Shenoy MU, Haque S, et al. Recognition and treatment of genitourinary complications in paediatric Crohn's disease using Infliximab. Acta Paediatr. 2010;99:1042-1046.
41. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999;117: 761-769. (Pubitemid 29468216)
42. Wewer V, Riis L, Vind I, et al. Infliximab dependency in a national cohort of children with Crohn's disease. J Pediatr Gastroenterol Nutr. 2006;42:40-45. (Pubitemid 43061008)
43. Duricova D, Pedersen N, Lenicek M, et al. Infliximab dependency in children with Crohn's disease. Aliment Pharmacol Ther. 2009;29:792-799.
44. Sinitsky DM, Lemberg DA, Leach ST, et al. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease. J Gastroenterol Hepatol. 2010;25:810-816.
45. de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm Bowel Dis. 2008;14:353-358. (Pubitemid 351441324)
46. De Bie CI, Hummel TZ, Kindermann A, et al. The duration of effect of infliximab maintenance treatment in paediatric Crohn's disease is limited. Aliment Pharmacol Ther. 2011;33:243-250.
47. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis. 2009;15:816-822.
48. Crombé V, Salleron J, Savoye G, et al. Long-term outcome of treatment with infliximab in pediatric-onset Crohn's disease: a population-based study. Inflamm Bowel Dis. 2011 [Epub ahead of print].
49. Hyams J, Walters TD, Crandall W, et al. Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn's disease in children: REACH open-label extension. Curr Med Res Opin. 2011;27:651-662.
50. Heuschkel R, Salvestrini C, Beattie RM, et al. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:839-849. (Pubitemid 351898069)
51. Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn's disease. Nat Rev Gastroenterol Hepatol. 2009;6:513-523.
52. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis. 2007;13:424-430. (Pubitemid 46668247)
53. Malik S, Wong SC, Bishop J, et al. Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr. 2011;52:31-37.
54. Diamanti A, Basso MS, Gambarara M, et al. Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients. Int J Colorectal Dis. 2009;24:19-25.
55. Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48:168-174.
56. Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol. 2008;6:1378-1384.
57. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. (Pubitemid 41770166)
58. Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis. 2011 [Epub ahead of print].
59. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. (Pubitemid 40824691)
60. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250-1260; quiz 1520.
61. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology. 2010;138:2282-2291.
62. Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol. 2010;105:1430-1436.
63. Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel therapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2002;34:307-311. (Pubitemid 34437526)
64. Mamula P, Markowitz JE, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr. 2004;38:298-301.
65. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic childhood ulcerative colitis. J Pediatr Gastroenterol Nutr. 2004;39: 166-170.
66. Eidelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis. 2005;11:213-218. (Pubitemid 40439675)
67. Fanjiang G, Russell GH, Katz AJ. Short- and long-term response to and weaning from infliximab therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2007;44:312-317. (Pubitemid 46673377)
68. Cucchiara S, Romeo E, Viola F, et al. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig Liver Dis. 2008;40 Suppl 2:S260-264. (Pubitemid 351878069)
69. McGinnis JK, Murray KF. Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol. 2008;42:875-879.
70. Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis. 2011;17:440-449.
71. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333; quiz 591.
72. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. (Pubitemid 47300424)
73. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65. (Pubitemid 46108762)
74. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829-838. (Pubitemid 351650483)
75. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-787.
76. Hyams J, Griffiths AM, Markowitz J, et al. Induction and maintenance adalimumab therapy for the treatment of moderate to severe Crohn's disease in children. J Crohns Colitis. 2011;5:S5-6.
77. Rosh JR, Lerer T, Markowitz J, et al. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease. Am J Gastroenterol. 2009;104:3042-3049.
78. Russell RK, Wilson ML, Loganathan S, et al. A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2011;33:946-953.
79. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease. Am J Gastroenterol. 2009;104:2566-2571.
80. Wyneski MJ, Green A, Kay M, et al. Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2008;47:19-25.
81. Rosenbach Y, Hartman C, Shapiro R, et al. Adalimumab treatment in children with refractory Crohn's disease. Dig Dis Sci. 2010;55:747-753.
82. Noe JD, Pfefferkorn M. Short-term response to adalimumab in childhood inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:1683-1687.
83. Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factoralpha antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr. 2005;41:357-359. (Pubitemid 41285833)
84. Hadziselimovic F. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2008;46:208-211. (Pubitemid 351161129)
85. Martin-de-Carpi J, Pociello N, Varea V. Long-term efficacy of adalimumab in paediatric Crohn's disease patients naive to other anti-TNF therapies. J Crohns Colitis. 2010;4:594-598.
86. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007;357:228-238. (Pubitemid 47080387)
87. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250. (Pubitemid 47080388)
88. Hanauer SB, Panes J, Colombel JF, et al. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther. 2010;32:384-393.
89. Jose FA, Garnett EA, Vittinghoff E, et al. Development of extraintestinal manifestations in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:63-68.
90. Dotson JL, Hyams JS, Markowitz J, et al. Extraintestinal manifestations of pediatric inflammatory bowel disease and their relation to disease type and severity. J Pediatr Gastroenterol Nutr. 2010;51:140-145.
91. Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr. 2003;37:150-154. (Pubitemid 39274541)
92. Escher JC, Stoof TJ, van Deventer SJ, et al. Successful treatment of metastatic Crohn disease with infliximab. J Pediatr Gastroenterol Nutr. 2002;34:420-423. (Pubitemid 34568549)
93. Krishnan S, Banquet A, Newman L, et al. Lung lesions in children with Crohn's disease presenting as nonresolving pneumonias and response to infliximab therapy. Pediatrics. 2006;117:1440-1443. (Pubitemid 46071543)
94. Silbermintz A, Krishnan S, Banquet A, et al. Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J Pediatr Gastroenterol Nutr. 2006; 42:324-326.
95. Carpenter E, Jackson MA, Friesen CA, et al. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. J Pediatr. 2004;144:541-544. (Pubitemid 38457363)
96. Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr. 2002;34:558-560. (Pubitemid 34596227)
97. Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm Bowel Dis. 2009;15:803-806.
98. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113:308-314. (Pubitemid 43170781)
99. Kahn P, Weiss M, Imundo LF, et al. Favorable response to highdose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113:860-864 e862.
100. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149:572-575. (Pubitemid 44468085)
101. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91:319-324. (Pubitemid 46586527)
102. Gallagher M, Quinones K, Cervantes-Castaneda RA, et al. Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol. 2007;91:1341-1344. (Pubitemid 47492870)
103. Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1424-1429. (Pubitemid 350206857)
104. Dubinsky MC, Mei L, Friedman M, et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2010;16:1357-1366.
105. D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011;106:199-212; quiz 213.
106. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123-128. (Pubitemid 46806219)
107. Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104-111. (Pubitemid 36135177)
108. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1124-1129. (Pubitemid 44311642)
109. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003;348:601-608. (Pubitemid 36204954)
110. Miele E, Markowitz JE, Mamula P, et al. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr. 2004;38:502-508.
111. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553. (Pubitemid 38834038)
112. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1248-1254. (Pubitemid 44512213)
113. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology. 2008;134:1861-1868. (Pubitemid 351790744)
114. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
115. Kugathasan S, Saubermann LJ, Smith L, et al. Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut. 2007;56:1696-1705. (Pubitemid 350206296)
116. Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. 2008;14:949-954.
117. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660-667. (Pubitemid 351284485)
118. Persley K, Scherl E, Rubin P. Avoidance of steroids by the early use of infliximab and 6-mercaptopurine in an adolescent with active Crohn's colitis. Am J Gastroenterol. 2001;96:3444-3445. (Pubitemid 34016680)
119. de Ridder L, Benninga MA, Taminiau JA, et al. Infliximab as first-line therapy in severe pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2006;43:388-390. (Pubitemid 44368198)
120. Lee JS, Lee JH, Lee HJ, et al. Efficacy of early treatment with infliximab in pediatric Crohn's disease. World J Gastroenterol. 2010;16: 1776-1781.
121. Candon S, Mosca A, Ruemmele F, et al. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin Immunol. 2006;118:11-19. (Pubitemid 43012041)
122. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003;124:917-924. (Pubitemid 36389794)
123. West RL, Zelinkova Z, Wolbink GJ, et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008;28:1122-1126.
124. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology. 2009;137:1628-1640.
125. Jacobstein DA, Markowitz JE, Kirschner BS, et al. Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm Bowel Dis. 2005; 11:442-446. (Pubitemid 40704078)
126. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther. 2003;17:75-84. (Pubitemid 36140437)
127. Friesen CA, Calabro C, Christenson K, et al. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2004;39:265-269.
128. Kugathasan S, Levy MB, Saeian K, et al. Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol. 2002;97:1408-1414. (Pubitemid 34664785)
129. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501-508.
130. Sarzi-Puttini P, Ardizzone S, Manzionna G, et al. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003;35:814-817. (Pubitemid 41070514)
131. Zella GC, Weinblatt ME, Winter HS. Drug-induced lupus associated with infliximab and adalimumab in an adolescent with Crohn disease. J Pediatr Gastroenterol Nutr. 2009;49:355-358.
132. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003;125:32-39. (Pubitemid 36799104)
133. Pastore S, Londero M, Gortani G, et al. Infliximab-related vasculitis in patients affected by ulcerative colitis. J Pediatr Gastroenterol Nutr. 2010;51:226-228.
134. Chuang MH, Singh J, Ashouri N, et al. Listeria meningitis after infliximab treatment of ulcerative colitis. J Pediatr Gastroenterol Nutr. 2010;50:337-339.
135. Francolla KA, Altman A, Sylvester FA. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J Pediatr Gastroenterol Nutr. 2008;47:193-195.
136. Nasir A, El Bahesh E, Whitten C, et al. Pityrosporum folliculitis in a Crohn's disease patient receiving infliximab. Inflamm Bowel Dis. 2010;16:7-8.
137. Dotson JL, Crandall W, Mousa H, et al. Presentation and outcome of histoplasmosis in pediatric inflammatory bowel disease patients treated with antitumor necrosis factor alpha therapy: a case series. Inflamm Bowel Dis. 2011;17:56-61.
138. Reichardt P, Dahnert I, Tiller G, et al. Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus)after treatment with infliximab in a boy with Crohn disease. Eur J Pediatr. 2002;161:281-283. (Pubitemid 34492690)
139. Pickering O, Weinstein T, Rubin LG. Fatal disseminated cytomegalovirus infection associated with infliximab and 6-mercaptopurine therapy in a child with Crohn disease. Pediatr Infect Dis J. 2009;28:556.
140. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91.
141. Sherlock ME, Bandsma R, Ota K, et al. Severe neutropenia following infliximab treatment in a child with ulcerative colitis. Inflamm Bowel Dis. 2011;17:E17-18.
142. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285. (Pubitemid 43736578)
143. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766.
144. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
145. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386-388.
146. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030. (Pubitemid 47309975)
147. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36-41 e31.
148. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62:2517-2524.
149. Deneau M, Wallentine J, Guthery S, et al. Natural killer cell lymphoma in a pediatric patient with inflammatory bowel disease. Pediatrics. 2010;126:e977-981.
150. Zamvar V, Sugarman ID, Tawfik RF, et al. Posterior reversible encephalopathy syndrome following infliximab infusion. J Pediatr Gastroenterol Nutr. 2009;48:102-105.
151. Zamvar V, Puntis JW. Re: "Posterior reversible encephalopathy syndrome following infliximab infusion." J Pediatr Gastroenterol Nutr. 2010;50:353.
152. Kolho KL, Ruuska T, Savilahti E. Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease. Acta Paediatr. 2007;96:128-130.
153. Kachko L, Efrat R, Ami SB, et al. Complex regional pain syndrome type I after infliximab infusion. Paediatr Anaesth. 2007;17:1112-1114. (Pubitemid 47481119)
154. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med. 2003;138:807-811.
155. Barbato M, Curione M, Viola F, et al. Cardiac involvement in children with IBD during infliximab therapy. Inflamm Bowel Dis. 2006;12:828-829. (Pubitemid 44253769)
156. Hiremath G, Duffy L, Leibowitz I. Infliximab-induced psoriasis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;52:230-232.
157. Eshuis EJ, Magnin KM, Stokkers PC, et al. Suicide attempt in ulcerative colitis patient after 4 months of infliximab therapy - a case report. J Crohns Colitis. 2010;4:591-593.
158. Roblin X, Oltean P, Heluwaert F, et al. Panic attack with suicide: an exceptional adverse effect of infliximab. Dig Dis Sci. 2006;51:1056. (Pubitemid 44127053)
159. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385-2392. (Pubitemid 40039370)
160. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
161. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846-1854,
162. Johnson DL, Jones KL, Chambers CD, et al. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology. 2009;136:A27.
163. Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther. 2005;21:733-738. (Pubitemid 40469001)
164. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228-233.
165. Mahadevan U, Terdiman JP, Church J, et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology. 2007;132:A144.
166. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-1058.
167. Mahadevan U, Miller JK, Wolf DC. Adalimumab levels detected in cord blood and infants exposed in utero. Gastroenterology. 2011;140:S61-62.
168. Mahadevan U, Kane SV, Church JA, et al. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology. 2008;134:A69.
169. Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010;4:603-605.
170. Mahadevan U, Cucchiara S, Hyams JS, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106:214-223; quiz 224.
171. Mahadevan U, Abreu MT. Certolizumab use in pregnancy: low levels detected in cord blood. Gastroenterology. 2009;136:A146.